Table 6. TUR plus delayed short-term instillations versus TUR plus delayed long-term instillations.
| Study | Year | Drug | % single tumors | Recurrence/total no. of patients | p | |
|---|---|---|---|---|---|---|
| TUR + delayed short- term instillations | TUR + delayed long- term instillations | |||||
| Long-term instillations: 1 yr | ||||||
| Bouffioux [13] | 1995 | MMC 30 mg/50 ml | 62% | 86/154 (55.8%) | 63/153 (41.2%) | 0.01 |
| ADM 50 mg/50 ml | ||||||
| Hendricksen [18] | 2007 | Epirubicin 50 mg/50 ml | 20% | 117/239 (49.0%) | 118/254 (46.5%) | 0.58 |
| Nomata [21] | 2002 | Epirubicin 30 mg/30 ml | 56% | NA/70 (44.9%) | NA/55 (51.5%) | NS |
| 3 yr | 3 yr | |||||
| Rubben [22] | 1988 | ADM 50 mg/50 ml | 68% | NA/91 (55%) | NA/88 (57%) | NS |
| 5 yr | 5 yr | |||||
| Kuroda [23] | 2004 | Epirubicin | 18% | 0.04† | ||
| 40 mg/40 ml (4mo) | NA/205 (39.9%) | NA/205 (51.3%) | ||||
| 30 mg/40 ml (7mo) | NA/204 (44.9%) | NA/205 (51.3%) | ||||
| vs. 20 mg/40 ml (12 mo) | 2 yr | 2 yr | ||||
| Long-term instillations: 2 yr | ||||||
| Flamm [24] | 1989 | Epodyl | Single | 15/44 (34.1%) | 17/46 (37.0%) | 0.78 |
| 50 cc | Multiple | 7/12 (58.3%) | 6/12 (50.0%) | 0.68 | ||
| 79% | 22/56 (39.3%) | 23/58 (39.7%) | 0.97 | |||
| Flamm [25] | 1990 | ADM 50 mg/50 ml | 48% | 32/76 (42.1%) | 33/70 (47.1%) | 0.78* |
| Total 2 yr | 54/132 (40.9%) | 56/128 (43.8%) | 0.63 | |||
| Long-term instillations: 3 yr | ||||||
| Huland [26a] | 1990 | MMC | NA | 15/75 (20.0%) | 17/96 (17.7%) | 0.70 |
| Schwaibold [27a] | 1997 | 20 mg/20 ml | ||||
| Huland [26b] | 1990 | MMC | NA | 15/75 (20.0%) | 51/209 (24.4%) | 0.44 |
| Schwaibold [27b] | 1997 | 20 mg/20 ml | ||||
| Friedrich [28] | 2007 | MMC 20 mg/20 ml | 64% | 46/179 (25.7%) | 16/153 (10.5%) | 0.0006* |
Treatment schedules: reference 13: 4 weekly instillations starting 1–2 wk after TUR followed by 5 or 11 monthly instillations to month 6 or 12 (9 or 15 instillations); reference 18: 4 weekly and then 5 monthly instillations to month 6 followed or not by two 3 monthly instillations to month 12 (9 or 11 instillations); reference 21: 4 weekly and then 8 twice monthly instillations to month 5 followed or not by 7 monthly instillations to month 12 (12 or 19 instillations); reference 22: twice weekly for 6 wk followed or not by twice monthly for 4.5 mo and then monthly instillations to month 12 (12 or 27 instillations); reference 23: weekly for 2 wk and every 2 wk to month 4 followed or not by monthly instillations for 3 mo followed or not by monthly instillations to month 12 (9 [40 mg/40 ml], 12 [30 mg/40 ml], or 17 [20 mg/40 ml] instillations); reference 24: weekly instillations for 6 wk followed or not by monthly instillations during 2 yr (6 or 30 instillations); reference 25: weekly instillations for 6 wk followed or not by monthly instillations during 2 yr (6 or 30 instillations); references 26a, 27a: weekly instillations for 20 wk versus weekly instillations for 8 wk followed by monthly instillations to 3 yr (20 or 42 instillations); references 26b, 27b: weekly instillations for 20 wk versus instillations every 2 wk during 1 yr, then every 4 wk during year 2, then every 3 mo during year 3 (20 or 42 instillations); reference 28: 6 weekly instillations followed or not by monthly instillations during 3 yr (6 or 42 instillations).
TUR = transurethral resection; MMC = mitomycin C; ADM = Adriamycin; NA = not available; NS = not significant.
Log-rank test.
Log-rank test for trend.